Abstract
Here we provide proof that the injection of tumor cells engineered to secrete interleukin 2 (IL-2)-IgG chimeric proteins locally induces potent antitumor responses, which are more effective than tumour transfection with IL-2 alone. Murine plasmacytoma cells (J558L) were stably transfected with DNA coding for a human IL-2-IgG1 or a murine IL-2-IgG2b fusion protein and were injected s.c. into syngeneic BALB/c mice. Evaluation of tumor growth and rejection patterns showed that IL-2-IgG secretion by transfected J558L tumor cells induced their rejection in all animals tested, similar to the rejection of J558L cells engineered to secrete IL-2 alone, whereas treatment with parental cells was lethal. However, mice treated with IL-2-IgG-s g J558L cells (human IL-2-IgG1 and murine IL-2-IgG2b) exhibited a significantly stronger tumor immunity against a later challenge with parental J558L cells than mice treated with IL-2-secreting tumor cells.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 2707-2710 |
| Number of pages | 4 |
| Journal | Cancer Research |
| Volume | 58 |
| Issue number | 13 |
| State | Published - Jul 1 1998 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Oncology
- Cancer Research
Cite this
Vaccination with tumor cells engineered to secrete interleukin 2- immunoglobulin G fusion protein induces tumor rejection. / Bulfone-Paus, Silvia; Von Bernuth, Horst; Rückert, René; Wachtlin, Joachim; Ungureanu, Daniela; Notter, Michael; Krause, Hans; Pohl, Thomas; Paus, Ralf; Kunzendorf, Ulrich.
In: Cancer Research, Vol. 58, No. 13, 01.07.1998, p. 2707-2710.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Vaccination with tumor cells engineered to secrete interleukin 2- immunoglobulin G fusion protein induces tumor rejection
AU - Bulfone-Paus, Silvia
AU - Von Bernuth, Horst
AU - Rückert, René
AU - Wachtlin, Joachim
AU - Ungureanu, Daniela
AU - Notter, Michael
AU - Krause, Hans
AU - Pohl, Thomas
AU - Paus, Ralf
AU - Kunzendorf, Ulrich
PY - 1998/7/1
Y1 - 1998/7/1
N2 - Here we provide proof that the injection of tumor cells engineered to secrete interleukin 2 (IL-2)-IgG chimeric proteins locally induces potent antitumor responses, which are more effective than tumour transfection with IL-2 alone. Murine plasmacytoma cells (J558L) were stably transfected with DNA coding for a human IL-2-IgG1 or a murine IL-2-IgG2b fusion protein and were injected s.c. into syngeneic BALB/c mice. Evaluation of tumor growth and rejection patterns showed that IL-2-IgG secretion by transfected J558L tumor cells induced their rejection in all animals tested, similar to the rejection of J558L cells engineered to secrete IL-2 alone, whereas treatment with parental cells was lethal. However, mice treated with IL-2-IgG-s g J558L cells (human IL-2-IgG1 and murine IL-2-IgG2b) exhibited a significantly stronger tumor immunity against a later challenge with parental J558L cells than mice treated with IL-2-secreting tumor cells.
AB - Here we provide proof that the injection of tumor cells engineered to secrete interleukin 2 (IL-2)-IgG chimeric proteins locally induces potent antitumor responses, which are more effective than tumour transfection with IL-2 alone. Murine plasmacytoma cells (J558L) were stably transfected with DNA coding for a human IL-2-IgG1 or a murine IL-2-IgG2b fusion protein and were injected s.c. into syngeneic BALB/c mice. Evaluation of tumor growth and rejection patterns showed that IL-2-IgG secretion by transfected J558L tumor cells induced their rejection in all animals tested, similar to the rejection of J558L cells engineered to secrete IL-2 alone, whereas treatment with parental cells was lethal. However, mice treated with IL-2-IgG-s g J558L cells (human IL-2-IgG1 and murine IL-2-IgG2b) exhibited a significantly stronger tumor immunity against a later challenge with parental J558L cells than mice treated with IL-2-secreting tumor cells.
UR - http://www.scopus.com/inward/record.url?scp=15644379905&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=15644379905&partnerID=8YFLogxK
M3 - Article
VL - 58
SP - 2707
EP - 2710
JO - Journal of Cancer Research
JF - Journal of Cancer Research
SN - 0099-7013
IS - 13
ER -